ArticleReviews in urology2009
Medical management of lower urinary tract symptoms.
Article in Reviews in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.The Journal of urology · 2019Trial
- Smooth muscle of the lower urinary tract: BK-RyR coupling in physiology and pathophysiology.Journal of muscle research and cell motility · 2025Review
- Article
- Article
- Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.International urology and nephrology · 2023Article
- Article
- The impact of short term, long term and intermittentAmerican journal of clinical and experimental urology · 2023Article
- The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia.American journal of clinical and experimental urology · 2023Review
- The IL-4/IL-13 signaling axis promotes prostatic fibrosis.PloS one · 2022Article
- CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling.PloS one · 2016Article
- Promising molecular targets and biomarkers for male BPH and LUTS.Current urology reports · 2013Review
- Prostatic fibrosis, lower urinary tract symptoms, and BPH.Nature reviews. Urology · 2013Review
- Prostatic fibrosis is associated with lower urinary tract symptoms.The Journal of urology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as alpha-blockers, 5alpha-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the alpha(1A)-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the alpha(1A)-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.
Indexed as
Identifiers
20126608PMC2812890W29556398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.